Lingonberries reduce atherosclerosis in Apoe(-/-) mice in association with altered gut microbiota composition and

Chrysoula Matziouridou1, Nittaya Marungruang1, Thao Duy Nguyen1

  • 1Food for Health Science Centre, Lund University, Lund, Sweden.

Abstract

Insights

Lingonberries reduced atherosclerosis and triglyceride levels in mice. These benefits were linked to changes in gut bacteria, metabolites, and increased bile acid gene expression.

Area of Science:

  • Nutritional Science
  • Cardiovascular Research
  • Microbiome Research

Background:

  • Atherosclerosis is a significant cardiovascular disease.
  • Dietary interventions, including berries, are explored for prevention.
  • The role of gut microbiota in metabolic health is increasingly recognized.

Purpose of the Study:

  • To evaluate lingonberry efficacy in preventing atherosclerosis in susceptible mice.
  • To investigate the association between lingonberry consumption, gut microbiota, metabolites, and lipid metabolism.

Main Methods:

  • Atherosclerosis-prone Apoe(-/-) mice were fed low-fat, high-fat, or high-fat with lingonberry diets for 8 weeks.
  • Analyses included blood lipid profiles, hepatic gene expression (Cyp7a1), atherosclerotic plaque quantification, gut microbiota (16S rRNA), and cecal short-chain fatty acids (SCFAs).

Main Results:

  • Lingonberry consumption significantly decreased triglyceride levels and atherosclerotic plaque formation compared to the high-fat diet group.
  • Hepatic expression of bile acid synthesis gene Cyp7a1 was upregulated in the lingonberry group.
  • Lingonberries altered gut microbiota composition, increasing Bacteroides, Parabacteroides, and Clostridium, and modified SCFA profiles, with lower total SCFAs but higher propionic acid.

Conclusions:

  • Lingonberries effectively reduce triglyceridemia and atherosclerosis in mice.
  • The observed benefits are associated with alterations in gut microbiota and SCFA profiles, potentially mediated by increased hepatic bile acid synthesis.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
577
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.9K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
732
Inflammation01:38

Inflammation

Overview
64.1K